The Chicago Entrepreneur

Moderna says FDA delayed RSV vaccine approval to end of May

The FDA has not informed Moderna of any issues related to the vaccine’s safety, efficacy or quality that would prevent its approval, the biotech company said.

Previous post Markets reprice Bank of England rate-cut bets as UK records fastest growth in nearly 3 years
Next post Moderna says FDA will not complete review of RSV vaccine by May 12 deadline